Related Experiment Video
Updated: May 27, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Peripheral antinociception induced by δ-opioid receptors activation, but not μ- or κ-, is mediated by Ca²⁺-activated
Daniela da Fonseca Pacheco1, Cinthia Mara da Fonseca Pacheco, Igor Dimitri Gama Duarte
1Department of Pharmacology, Institute of Biological Sciences, UFMG, Av. Antônio Carlos, 6627, CEP: 31.270.100, Belo Horizonte, Brazil.
Abstract:
Studies have demonstrated that the L-arginine/NO/cGMP pathway and the potassium and calcium channels are involved in the mechanisms underlying opioid receptor activation. As additional pathways may participate in the observed antinociceptive effects following opioid exposure, the aim of our study was to determine whether Ca(2+)-activated Cl(-) channels (CaCCs) are involved in peripheral antinociception induced by μ-, δ- and κ-opioid receptor activation. Hyperalgesia was induced by intraplantar injection of prostaglandin E(2) (PGE(2), 2 μg). Nociceptive thresholds to pressure (grams) were measured using an algesimetric apparatus 3h following injection. The μ-opioid receptor agonist morphine (200 μg), δ-opioid receptor agonist (+)-4-[(alphaR)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80, 80 μg), κ-opioid receptor agonist bremazocine (50 μg), CaCCs blocker niflumic acid (8-64 μg), CaCCs blocker 5-Nitro-2-(3-phenylpropylamino) benzoic acid (NPPB, 32-128 μg), nitric oxide donor sodium nitroprusside (SNP, 500 μg) and cGMP exogenous analogs dibutyryl cGMP (db-cGMP, 100 μg) were also administered into the paw. The CaCCs blocker niflumic acid and NPPB partially reversed the peripheral antinociception induced by exposure to the SNC80 in a dose-dependent manner. In contrast, niflumic acid did not modify the antinociceptive effect observed following exposure to morphine or bremazocine. Additionally, the peripheral antinociception induced by the NO donor SNP or by db-cGMP was not inhibited by niflumic acid. These results provide evidence for the involvement of CaCCs in the peripheral antinociception induced by SNC80. CaCCs activation does not appear to be involved when μ- and κ-opioid receptors are activated. In addition, we did not observe a link between CaCCs and the L-arginine/NO/GMPc pathway.
Insights
Calcium-activated chloride channels (CaCCs) are involved in peripheral pain relief from delta-opioid receptor activation. However, CaCCs do not play a role in pain relief mediated by mu- or kappa-opioid receptors or the nitric oxide pathway.
Area of Science:
- Pharmacology
- Neuroscience
- Pain Research
Background:
- Opioid receptor activation involves the L-arginine/NO/cGMP pathway and ion channels.
- Peripheral antinociception mechanisms following opioid exposure require further elucidation.
- The potential role of Ca(2+)-activated Cl(-) channels (CaCCs) in opioid-induced analgesia is unexplored.
Purpose of the Study:
- To investigate the involvement of CaCCs in peripheral antinociception induced by mu-, delta-, and kappa-opioid receptor activation.
- To determine if CaCCs mediate pain relief through the L-arginine/NO/cGMP pathway.
Main Methods:
- Hyperalgesia was induced using prostaglandin E(2) (PGE(2)) in an animal model.
- Nociceptive thresholds were measured after administration of opioid receptor agonists (morphine, SNC80, bremazocine) and CaCCs blockers (niflumic acid, NPPB).
- The effects of nitric oxide (NO) donor (SNP) and cGMP analog (db-cGMP) on antinociception were assessed in the presence of CaCCs blockers.
Main Results:
- CaCCs blockers partially reversed the antinociception induced by the delta-opioid receptor agonist SNC80 in a dose-dependent manner.
- CaCCs blockers did not affect the antinociceptive effects of the mu-opioid receptor agonist morphine or the kappa-opioid receptor agonist bremazocine.
- Niflumic acid did not inhibit antinociception induced by the NO donor SNP or db-cGMP, indicating no link between CaCCs and the L-arginine/NO/cGMP pathway.
Conclusions:
- CaCCs are involved in peripheral antinociception specifically mediated by delta-opioid receptor activation.
- CaCCs activation is not implicated in the peripheral antinociceptive effects of mu- and kappa-opioid receptor agonists.
- The L-arginine/NO/cGMP pathway is not linked to CaCCs in the context of opioid-induced peripheral antinociception.
Related Concept Videos
Opioid Receptors: Overview
Analgesia and Pain Management
Nociception
Pain
Mechanically-gated Ion Channels
Local Anesthetics: Differential Sensitivity of Nerve Fibers
